{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-090183","form_type":"8-K","ticker":"ALLR","cik":"0001860657","company_name":"Allarity Therapeutics, Inc.","filed_at":"2026-08-14T20:35:17+00:00","discovered_at":"2026-08-14T20:40:32.717277+00:00","generated_at":"2026-08-14T20:40:58.969662+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Allarity Q2 2026: cash $26.9M, loss $3.7M; stenoparib manufacturing completed","bullets":["Cash and restricted cash $26.9M at June 30, 2026, up from $14.7M a year ago.","Q2 comprehensive loss $3.7M vs $4.2M; six-month loss $6.5M vs $7.2M.","R&D expenses $1.3M (down from $2.3M); G&A $1.3M (down from $1.8M).","Completed Phase 3-ready stenoparib API manufacturing campaign in July 2026, ahead of schedule.","USPTO granted key patent for stenoparib DRP companion diagnostic, exclusivity to 2042."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-090183","json":"https://secwatch.observer/filing/0001213900-26-090183.json","markdown":"https://secwatch.observer/filing/0001213900-26-090183.md","text":"https://secwatch.observer/filing/0001213900-26-090183.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1860657/000121390026090183/0001213900-26-090183-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1860657/000121390026090183/ea0302157-8k_allarity.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-14T20:40:58.969662+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}